Tapinarof for Psoriasis: Two Japanese Trials

The controlled result

The ZBA4-1 trial randomized 158 adults to tapinarof 1% or vehicle cream for twelve weeks. Most were men. Eligible disease covered 3–20% of body surface, excluding hairy scalp. Physician-rated clear or almost clear skin plus ≥2-grade improvement occurred in 20.06% versus 2.50%, using multiple imputation for missing observations.¹

Contact dermatitis affected 13/106 versus 0/52 during treatment; adverse-event withdrawals were 15/106 versus 4/52. Neither trial compared another psoriasis medicine.¹

A separate year

ZBA4-2 treated 305 people without a control group for 52 weeks; 228 completed. Its week-52 56.3% success rate used available observations, without imputing missing outcomes. Rescue medicines were used by 94/304 evaluable participants; topical corticosteroids were most common.¹

Japan Tobacco funded both trials; three authors were employees, two disclosed company grants or fees. The year-long result cannot isolate the cream’s contribution.¹

Prescription discussion

The US VTAMA label covers plaque psoriasis in adults. Its eczema indication extends to children aged two or older; that does not establish a pediatric psoriasis indication. Apply a thin layer once daily as prescribed, wash hands afterward unless treating them, and keep it out of the mouth, eyes and vagina.²

The label lists folliculitis and contact dermatitis among common psoriasis adverse reactions. Report new bumps or an irritated rash to the prescriber instead of assuming every change is psoriasis. Available pregnancy data are insufficient to evaluate drug-associated risk; breastfeeding effects are unknown. Discuss pregnancy plans or breastfeeding before treatment.²

The American Academy of Dermatology³ bases treatment choice on the psoriasis type, location, severity, impact on daily life, other conditions and medicines. A topical may be combined with light therapy or systemic treatment. Tell the dermatologist about joint pain, swelling or morning stiffness as well as skin symptoms.³

Bring a question tied to the affected sites: “What improvement should we look for, and what would make you change the prescription?” Record which patches bother you, previous treatments and any new irritation. Ask which changes need a call before the next appointment.³

Skin, Head to Toe includes “What to Say at the Appointment”: prepare the question, list products and medicines already tried, and describe how the skin problem affects your day. Bring those notes to the prescription discussion.